Porton Pharma Solutions Ltd(300363) reply to the concern letter: Based on the confidentiality agreement, it is inconvenient to unilaterally disclose the specific information of Pfizer’s order

On February 17, Porton Pharma Solutions Ltd(300363) replied to the letter of concern from Shenzhen Stock Exchange. In view of the specific name, amount, purpose or indication of the corresponding products or services, and whether they are related to covid-19 therapeutic drugs, the company said, As the terminal products of the company providing contract customized R & D and production (cdmo) services are innovative drugs with patent protection period, based on the confidentiality agreement signed between the company and customers, the name, purpose or indication, supporting process flow, patented technology, supplier and other information of the products belong to important trade Secrets of customers, so it is inconvenient for the company to disclose them unilaterally.